Core Viewpoint - The company has decided to temporarily use part of its idle raised funds, not exceeding 80 million RMB, to supplement its working capital for a period not exceeding 12 months, ensuring that this does not affect the normal operation of the fundraising investment projects [10][17][18]. Group 1: Meeting Resolutions - The sixth session of the board of supervisors held its 25th meeting on September 19, 2025, and approved the proposal to use part of the idle raised funds to temporarily supplement working capital with unanimous consent [1][2]. - The sixth session of the board of directors held its 30th meeting on September 19, 2025, and also approved the proposal to open a temporary supplementary fund account for managing the raised funds [4][5]. Group 2: Fund Usage Details - The company plans to use the idle raised funds for a maximum of 80 million RMB to supplement working capital, with the usage period starting from the board resolution date and lasting no more than 12 months [10][14]. - As of September 18, 2025, the company has cumulatively used 696.73 million RMB of the raised funds, with a remaining balance of 106.70 million RMB [11]. Group 3: Previous Fund Returns - The company previously approved the use of up to 100 million RMB of idle raised funds to supplement working capital, with 13 million RMB returned early on March 20, 2025, and the remaining 87 million RMB returned by September 18, 2025 [7][8][12]. Group 4: Justification for Fund Usage - The decision to use idle raised funds is aimed at improving fund utilization efficiency and reducing financial costs, with an estimated reduction in interest expenses of 2.4 million RMB based on the current loan market rate [16][19].

东方证券股份有限公司 关于金河生物科技股份有限公司 使用部分闲置募集资金 暂时补充流动资金的核查意见 东方证券股份有限公司（以下简称"保荐机构"）作为金河生物科技股份有 限公司（以下简称"金河生物"或"公司"）非公开发行股票的持续督导机构， 根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监管指 引第 1 号—主板上市公司规范运作》《深圳证券交易所股票上市规则》等相关法 律、法规和规范性文件的规定，对金河生物使用部分闲置募集资金暂时补充流动 资金事项进行了核查，具体情况如下： 一、募集资金情况 根据 2020 年 12 月 4 日中国证监会核发的《关于核准金河生物科技股份有限 公司非公开发行股票的批复》（证监许可[2020]3344 号）文核准，公司获准非公 开发行 145,132,743 股，每股面值人民币 1 元，发行价格为每股人民币 5.65 元， 实 际 募 集 资 金 总 额 为 819,999,997.95 元 ， 扣 除 不 含 税 发 行 费 用 人 民 币 17,756,396.62 元后，实际募集资金净额为 802,243,601.33 元。公司以上募集资金 已 经 信 永 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-085 2025 年 9 月 19 日 金河生物科技股份有限公司（以下简称"公司"）于 2024 年 9 月 23 日召开 了第六届董事会第十八次会议和第六届监事会第十五次会议审议通过《关于使用 部分闲置募集资金暂时补充流动资金的议案》。同意公司在确保不影响募集资金 投资项目实施及募集资金使用的情况下，使用不超过 10,000 万元的闲置募集资 金暂时补充公司流动资金，使用期限自董事会审议通过之日起不超过十二个月， 到期归还至募集资金专用账户。具体内容详见公司 2024 年 9 月 24 日于巨潮资讯 网（www.cninfo.com.cn）《证券日报》《证券时报》《中国证券报》《上海证 券报》披露的《关于使用部分闲置募集资金暂时补充流动资金的公告》（公告编 号：2024-089）。 在上述授权金额及期限内，公司实际用于暂时补充流动资金的非公开发行股 票暂时闲置的募集资金总额为 10,000 万元。 2025 年 3 月 20 日，公司已将用于暂时补充流动资金的闲置募集资金人民币 1,300 万元提前归还至公司募集资金专用账户。2025 年 9 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-088 金河生物科技股份有限公司 万元，尚未使用的募集资金余额为 10,670.19 万元（包括存款利息收入和手续费 支出的净额）。募集资金投资项目累计投入情况如下： | 单位：万元 | | --- | | | | | | 募集资金累 | | --- | --- | --- | --- | --- | | 序号 | 项目名称 | 项目实施主体 | 募集资金承 | 计投入金额 | | | | | 诺投资金额 | （含募集资 | | | | | | 金置换金额） | | 1 | 动物疫苗生产基地建设项目（一 | 金河佑本生物制 | 37,016.68 | 27,622.59 | | | 期） | 品有限公司 | | | | 2 | 新版 GMP 符合性技改项目 | 杭州佑本动物疫 苗有限公司 | 11,848.03 | 11,468.10 | | 3 | 生产工艺系统降耗增效改造项目 | 金河生物 | 5,561.13 | 4,370.18 | | 4 | 动力系统节能升级技改项目 | 金河生物 | 3,054.29 | 2,774.87 | | 5 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-087 金河生物科技股份有限公司 第六届监事会第二十五次会议决议公告 本公司及监事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）第六届监事会第二十五次 会议于 2025 年 9 月 16 日以电子邮件方式发出通知，并于 2025 年 9 月 19 日以通 讯方式召开。会议由监事会主席张千岁先生主持，应到监事 3 人，实到监事 3 人，本次监事会出席会议监事人数符合法律法规，会议合法有效。会议召开符合 《中华人民共和国公司法》等法律、法规和《公司章程》的规定。与会监事以通 讯表决的方式审议通过了以下议案： 一、以 3 票同意，0 票反对，0 票弃权审议通过了《关于使用部分闲置募集 资金暂时补充流动资金的议案》。 监事会认为：公司本次使用部分闲置募集资金暂时补充流动资金事项及审议 程序符合有关法律法规的规定，不会影响募集资金投资项目的正常进行，不存在 变相改变募集资金投向或损害股东利益的情况，且有利于提高募集资金使用效率、 降低公司的财务费用。因此，我们同 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-086 金河生物科技股份有限公司 第六届董事会第三十次会议决议公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）第六届董事会第三十次会 议于 2025 年 9 月 16 日以电子邮件方式发出通知，并于 2025 年 9 月 19 日以通讯 方式召开，会议由董事长王东晓先生主持，应到董事 9 人，实到董事 9 人，本次 董事会出席会议董事人数符合法律法规，会议合法有效。会议召开符合《中华人 民共和国公司法》等法律、法规和《公司章程》的规定。与会董事以通讯表决的 方式审议通过了以下议案： 一、以 9 票同意，0 票反对，0 票弃权审议通过了《关于开立募集资金临时 补流专户的议案》。 董事会同意公司开立募集资金临时补流专户，用于存储及管理 2021 年非公 开发行 A 股股票临时补充流动资金的募集资金，该账户不得存放非募集资金或用 作其他用途。公司董事会授权管理层或其指定人员负责办理账户的开立及后续与 募集资金存放银行、保荐机构签署募集资金监管 ...

Market Overview - On September 19, the animal health sector declined by 0.26% compared to the previous trading day, with the driving force leading the decline [1] - The Shanghai Composite Index closed at 3820.09, down 0.3%, while the Shenzhen Component Index closed at 13070.86, down 0.04% [1] Stock Performance - Notable stock movements included: - *ST Lvkang (002868): Closed at 27.56, up 4.99% with a trading volume of 38,500 shares and a turnover of 105 million yuan [1] - Kexin Biological (688526): Closed at 18.08, up 0.39% with a trading volume of 22,700 shares and a turnover of 40.94 million yuan [1] - Driving Force (838275): Closed at 10.50, down 4.11% with a trading volume of 21,200 shares and a turnover of 22.63 million yuan [2] Capital Flow - The animal health sector experienced a net outflow of 91.4 million yuan from institutional investors, while retail investors saw a net inflow of 70.15 million yuan [2] - The capital flow for individual stocks showed: - RuiPu Biological (300119): Net inflow of 16.56 million yuan from institutional investors, but a net outflow of 21.57 million yuan from retail investors [3] - *ST Lvkang (002868): Net inflow of 6.13 million yuan from institutional investors, with a net outflow of 4.21 million yuan from retail investors [3]

Market Overview - On September 18, the animal health sector declined by 0.77% compared to the previous trading day, with Huisheng Biological leading the decline [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] Stock Performance - The following stocks in the animal health sector showed notable performance: - *ST Lvkang (002868): Closed at 26.25, up 5.00% with a trading volume of 3433 lots [1] - Shengbi Biological (600201): Closed at 66.8, down 2.39% with a trading volume of 55.74 million [1] - Ruipu Biological (300119): Closed at 22.06, unchanged with a trading volume of 111.3 million [1] - Other stocks such as Jinhai Biological (002688) and Shunlian Biological (688098) also experienced declines of 1.98% and 2.02% respectively [1][2] Capital Flow - The animal health sector experienced a net outflow of 126 million yuan from institutional investors, while retail investors saw a net inflow of 92.38 million yuan [2] - The following stocks had significant capital flow: - Ruipu Biological: Net inflow of 12.35 million yuan from institutional investors [3] - *ST Lvkang: Net outflow of 3.83 million yuan from institutional investors [3] - Jinhai Biological: Net outflow of 25.51 million yuan from institutional investors [3]

Market Overview - On September 16, the animal health sector declined by 0.41%, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Stock Performance - Key stocks in the animal health sector showed mixed performance, with the following notable movements: - Xianfeng Holdings (002141) increased by 2.27% to close at 4.06 [1] - Haili Biological (603718) rose by 1.27% to 7.17 [1] - *ST Lvkang (002868) fell by 4.34% to 23.81, leading the decline [2] - The trading volume and turnover for selected stocks were significant, with Xianfeng Holdings achieving a turnover of 1.02 billion [1] Capital Flow Analysis - The animal health sector experienced a net outflow of 15.97 million from institutional investors, while retail investors saw a net inflow of 11.29 million [2][3] - Notable capital flows included: - Biological Shares (600201) had a net inflow of 12.28 million from institutional investors [3] - *ST Lvkang (002868) saw a net outflow of 2.89 million from institutional investors [3] - Retail investors contributed positively to several stocks, including a net inflow of 12.59 million into Shenyuan Biological (688098) [3]

Company Overview - Jinhe Biology Co., Ltd. is located in Inner Mongolia and was established on March 14, 1990, with its listing date on July 13, 2012 [2] - The company specializes in the production, sales, research, and service of animal health products, with a revenue composition of 61.83% from veterinary chemical drugs, 19.76% from starch and related products, 11.12% from veterinary vaccines, 4.97% from environmental services, and 2.15% from other sources [2] Financial Performance - For the first half of 2025, Jinhe Biology achieved a revenue of 1.39 billion yuan, representing a year-on-year growth of 30.45%, and a net profit attributable to shareholders of 138 million yuan, up 51.52% year-on-year [2] - The company has distributed a total of 877 million yuan in dividends since its A-share listing, with 227 million yuan distributed over the past three years [3] Stock Performance - As of September 16, Jinhe Biology's stock price was 7.05 yuan per share, with a market capitalization of 5.44 billion yuan [1] - The stock has increased by 61.22% year-to-date, with a recent 5-day increase of 1.29%, a 20-day decrease of 5.87%, and a 60-day increase of 12.44% [1] - The company has appeared on the trading leaderboard six times this year, with the most recent occurrence on April 16, where it recorded a net buy of -28.30 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 104.38% to 64,500, while the average circulating shares per person decreased by 51.07% to 11,547 shares [2] - Among the top ten circulating shareholders, Guotai Zhongzheng Livestock Breeding ETF is the third-largest shareholder, holding 7.66 million shares as a new investor [3]